Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidone.

Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidon

The effect of olive fruit stoning on virgin olive oil aroma

Olive fruit stoning gives rise to an important modification in olive oil aroma. The level of this modification is a function of the cultivar. An increment in the content of six-carbon compounds (C6) was observed in olive oils obtained from the cultivars Verdial and Manzanilla, but not in the cultivar Picual. In the three cultivars under study, contents of five-carbon compounds (C5) and esters decreased as a consequence of fruit stoning. The modification of olive oil aroma composition in the cultivar Verdial caused by olive fruit stoning was observed to be due both to tissue wounding and to the absence of the olive seed during the crushing-malaxation process to obtain olive oil aroma. Both factors contribute independently to the content modification of C6, C5 compounds and esters in the olive oil aroma from stoned fruits.El deshuesado de la aceituna da lugar a una importante modificación del aroma del aceite de oliva virgen. La intensidad de esta modificación es característica de cada variedad. En los aceites obtenidos de aceitunas Verdial y Manzanilla se produce un incremento en el contenido de los compuestos de seis átomos de carbono (C6) que no se detecta en la variedad Picual. En las tres variedades estudiadas se observa un descenso del contenido de compuestos de cinco átomos de carbono (C5) así como del contenido en ésteres. En la variedad Verdial se ha comprobado que la modificación del aroma como consecuencia del deshuesado del fruto se debe tanto al daño tisular generado durante este proceso como a la ausencia de la semilla durante la molturación de la aceituna. Ambos factores contribuyen de forma independiente a la modificación del contenido de compuestos C6, C5 y ésteres en el aroma del aceite de oliva virgen procedente de aceituna deshuesada.El trabajo se ha realizado en el marco del Proyecto de Investigación AGL2002-02307 del Programa Nacional de Recursos y Tecnologías Agroalimentarias.Peer reviewe

Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis

Rationale: While one of the basic axioms of pharmacology postulates that there is a relationship between the concentration and effects of a drug, the value of measuring blood levels is questioned by many clinicians. This is due to the often-missing validation of therapeutic reference ranges. Objectives: Here, we present a prototypical meta-analysis of the relationships between blood levels of aripiprazole, its target engagement in the human brain, and clinical effects and side effects in patients with schizophrenia and related disorders. Methods: The relevant literature was systematically searched and reviewed for aripiprazole oral and injectable formulations. Population-based concentration ranges were computed (N = 3,373) and pharmacokinetic influences investigated. Results: Fifty-three study cohorts met the eligibility criteria. Twenty-nine studies report blood level after oral, 15 after injectable formulations, and nine were positron emission tomography studies. Conflicting evidence for a relationship between concentration, efficacy, and side effects exists (assigned level of evidence low, C; and absent, D). Population-based reference ranges are well in-line with findings from neuroimaging data and individual efficacy studies. We suggest a therapeutic reference range of 120-270 ng/ml and 180-380 ng/ml, respectively, for aripiprazole and its active moiety for the treatment of schizophrenia and related disorders. Conclusions: High interindividual variability and the influence of CYP2D6 genotypes gives a special indication for Therapeutic Drug Monitoring of oral and long-acting aripiprazole. A starting dose of 10 mg will in most patients result in effective concentrations in blood and brain. 5 mg will be sufficient for known poor metabolizers

Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy

IntroductionA titration within a certain therapeutic reference range presupposes a relationship between the blood concentration and the therapeutic effect of a drug. However, this has not been systematically investigated for escitalopram. Furthermore, the recommended reference range disagrees with mean steady state concentrations (11–21 ng/ml) that are expected under the approved dose range (10–20 mg/day). This work systematically investigated the relationships between escitalopram dose, blood levels, clinical effects, and serotonin transporter occupancy.MethodsFollowing our previously published methodology, relevant articles were systematically searched and reviewed for escitalopram.ResultsOf 1,032 articles screened, a total of 30 studies met the eligibility criteria. The included studies investigated escitalopram blood levels in relationship to clinical effects (9 studies) or moderating factors on escitalopram metabolism (12 studies) or serotonin transporter occupancy (9 studies). Overall, the evidence for an escitalopram concentration/effect relationship is low (level C).ConclusionBased on our findings, we propose a target range of 20–40 ng/ml for antidepressant efficacy of escitalopram. In maintenance treatment, therapeutic response is expected, when titrating patients above the lower limit. The lower concentration threshold is strongly supported by findings from neuroimaging studies. The upper limit for escitalopram’s reference range rather reflects a therapeutic maximum than a tolerability threshold, since the incidence of side effects in general is low. Concentrations above 40 ng/ml should not necessarily result in dose reductions in case of good clinical efficacy and tolerability. Dose-related escitalopram concentrations in different trials were more than twice the expected concentrations from guideline reports.Systematic review registration[https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=215873], identifier [CRD42020215873]

Effect of dynamic compressive loading and its combination with a growth factor on the chondrocytic phenotype of 3-dimensional scaffold-embedded chondrocytes

Background and purpose Three-dimensionally (3D-) embedded chondrocytes have been suggested to maintain the chondrocytic phenotype. Furthermore, mechanical stress and growth factors have been found to be capable of enhancing cell proliferation and ECM synthesis. We investigated the effect of mechanical loading and growth factors on reactivation of the 3D-embedded chondrocytes

Redox and Ligand Exchange during the Reaction of Tetrachloroaurate with Hexacyanoferrate(II) at a Liquid-Liquid Interface: Voltammetry and X-ray Absorption Fine-Structure Studies

AbstractVoltammetry for charge (ion and electron) transfer at two immiscible electrolyte solutions (VCTIES) has been used to provide insight into the ligand exchange and redox processes taking place during the interfacial reaction of aqueous hexacyanoferrate(II) with tetrachloroaurate ([AuCl4]−) in 1,2-dichloroethane (DCE). VCTIES permitted the detection of the reactants, intermediates and products at the liquid/liquid interface. A model for the sequence of interfacial processes was established with the support of speciation analysis of the key elementary reactions by X-ray absorption spectroscopy (XAS). The potential-driven transfer of [AuCl4]− from the organic into the aqueous phase is followed by reduction and ligand exchange by the aqueous hexacyanoferrate(II) to form dicyanoaurate ([Au(CN)2]−). Inferences from the reactions point to the likely formation of [AuCl2]− during the reduction sequence. The reaction is influenced by ligand exchange equilibria between [AuCl4]−, [AuCl3(OH)]– and [AuCl2(OH)2]– which are shown to be dependent on the chloride ion concentration and pH of the solution. The difference between the Gibbs energy of transfer at the water | DCE interface (ΔGDCEW°)of AuCl4– and [AuCl3(OH)]–, and the difference between [AuCl3(OH)]– and [AuCl2(OH)2]– were found to change by a value close to the difference between ΔGDCEW° of Cl– and that of OH–. The intermediate Au(I) species, [AuCl2]−, was seen to decompose at neutral pH and in the absence of Cl– in water to form metallic Au, although it was stable in >10mM HCl for an hour. Time-dependent VCTIES and X-ray absorption fine structure (XAFS) speciation analysis of the homogeneous aqueous phase indicate that reaction between [AuCl4]− and hexacyanoferrate(II) is accompanied by the formation of an intermediate ionic species, formed when the concentration of [AuCl4]− is close to that of hexacyanoferrate(II). This species, whose identity was not precisely determined, was also generated by reaction between [AuCl2]− and hexacyanoferrate(III). The species is shown by VCTIES to be more hydrophilic than [Au(CN)2]−, [AuCl2]− and [AuCl4]−